SCB 219
Alternative Names: SCB-219; SCB-219MLatest Information Update: 28 Jul 2025
At a glance
- Originator Clover Biopharmaceuticals
- Class Bispecific antibodies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic thrombocytopenic purpura
- No development reported Thrombocytopenia
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Thrombocytopenia in China (SC, Injection)
- 28 Dec 2023 Pharmacokinetics, efficacy and adverse events data from a phase I trial in Thrombocytopenia released by Clover Biopharmaceuticals
- 28 Dec 2023 Clover Biopharmaceuticals plans a phase Ib trial in Thrombocytopenia in 2024